European Commission says no to drug-type pre-market evaluation for devices but authority role foreseen
This article was originally published in RAJ Devices
Executive Summary
The European Commission has said that transferring responsibility in the EU for assessing the safety and performance of medical devices from notified bodies to a regulatory authority and centralised authorisation as it exists in the pharmaceutical domain is, for the time being at least, "neither a feasible nor a desirable option".